CGMS vs DBD

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on CGMS as a result. In 28 of 63 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 44%.

The Moving Average Convergence Divergence (MACD) for CGMS just turned positive on October 09, 2026. Looking at past instances where CGMS's MACD turned positive, the stock continued to rise in 22 of 37 cases over the following month. The odds of a continued upward trend are 59%.

Following a +0.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGMS advanced for three days, in 146 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 33%.

CGMS broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CGMS entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on DBD as a result. In 43 of 53 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for DBD just turned positive on October 01, 2026. Looking at past instances where DBD's MACD turned positive, the stock continued to rise in 23 of 32 cases over the following month. The odds of a continued upward trend are 72%.

DBD moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +2.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where DBD advanced for three days, in 174 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

DBD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DBD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.

The Aroon Indicator for DBD entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. DBD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.387) is normal, around the industry mean (-1.734). P/E Ratio (22.275) is within average values for comparable stocks, (15.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.824). Dividend Yield (0.000) settles around the average of (0.074) among similar stocks. P/S Ratio (0.606) is also within normal values, averaging (71.128).

The Tickeron SMR rating for this company is 67 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.